Gemcitabine: progress in the treatment of pancreatic cancer
- PMID: 11150902
- DOI: 10.1159/000055290
Gemcitabine: progress in the treatment of pancreatic cancer
Abstract
Unresectable pancreatic cancer has a dismal prognosis with a median survival of 3-5 months in untreated disease. Since the introduction of gemcitabine, pancreatic cancer may no longer be regarded a chemotherapy-resistant tumor. Treatment with single-agent gemcitabine achieved clinical benefit and symptoms improvement in 20-30% of patients. While 1-year survival was observed in 2% of 5-fluorouracil (5-FU)-treated patients, it was raised to 18% by single-agent gemcitabine. Good treatment tolerability and low incidence of side effects are clear advantages of single-agent gemcitabine. Improvement of efficacy is, however, expected from combination treatment. Gemcitabine and cisplatin given as first-line treatment in three studies achieved a median survival of 7.4-8.3 months. One-year survival was raised to 28% as reported in one study. Comparable activity was obtained by a combination of gemcitabine with 5-FU. Nine studies using gemcitabine in combination with standard-dose or high-dose 5-FU reported a median survival ranging from 5.5 to 13 months. Notwithstanding these promising results, recommendations regarding palliative chemotherapy of pancreatic cancer remain tentative and still need confirmation by presently ongoing phase III trials. Inclusion of pancreatic cancer patients into clinical trials should be a major goal. Outside clinical trials, patients should present with an adequate PS (Karnofsky-performance index greater than or = 70) to qualify for chemotherapy.
Similar articles
-
Gemcitabine-based combination treatment of pancreatic cancer.Semin Oncol. 2002 Feb;29(1 Suppl 3):25-35. doi: 10.1053/sonc.2002.30749. Semin Oncol. 2002. PMID: 11894005 Review.
-
Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials.Semin Oncol. 2002 Dec;29(6 Suppl 20):9-16. doi: 10.1053/sonc.2002.37372. Semin Oncol. 2002. PMID: 12577228 Review.
-
[Gemcitabine-based combinations in inoperable pancreatic cancers].Bull Cancer. 2002 Aug;89 Spec No:S96-101. Bull Cancer. 2002. PMID: 12449038 Review. French.
-
Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.Oncologist. 2001;6(6):488-95. doi: 10.1634/theoncologist.6-6-488. Oncologist. 2001. PMID: 11743211
-
Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer.Anticancer Drugs. 2007 Mar;18(3):263-71. doi: 10.1097/CAD.0b013e3280121334. Anticancer Drugs. 2007. PMID: 17264757 Clinical Trial.
Cited by
-
WR-2721 reduces intestinal toxicity from concurrent gemcitabine and radiation treatment.Int J Pancreatol. 2001;29(1):19-23. doi: 10.1385/IJGC:29:1:19. Int J Pancreatol. 2001. PMID: 11558629
-
NPTX1 inhibits pancreatic cancer cell proliferation and migration and enhances chemotherapy sensitivity by targeting RBM10.Oncol Lett. 2022 May;23(5):154. doi: 10.3892/ol.2022.13275. Epub 2022 Mar 16. Oncol Lett. 2022. PMID: 35836482 Free PMC article.
-
Gemcitabine treatment of rat soft tissue sarcoma with phosphatidyldiglycerol-based thermosensitive liposomes.Pharm Res. 2014 Sep;31(9):2276-86. doi: 10.1007/s11095-014-1322-6. Epub 2014 Mar 6. Pharm Res. 2014. PMID: 24599802
-
Metabolic Adaptation during nab-Paclitaxel Resistance in Pancreatic Cancer Cell Lines.Cells. 2020 May 19;9(5):1251. doi: 10.3390/cells9051251. Cells. 2020. PMID: 32438599 Free PMC article.
-
Connecting dots between nucleotide biosynthesis and DNA lesion repair/bypass in cancer.Biosci Rep. 2024 Sep 25;44(9):BSR20231382. doi: 10.1042/BSR20231382. Biosci Rep. 2024. PMID: 39189649 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical